{"id":13973,"date":"2023-08-23T08:31:00","date_gmt":"2023-08-23T12:31:00","guid":{"rendered":"https:\/\/www.rigicon.com\/uncategorized\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment-2\/"},"modified":"2023-08-23T08:31:00","modified_gmt":"2023-08-23T12:31:00","slug":"new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment","status":"publish","type":"post","link":"https:\/\/www.rigicon.com\/pt-br\/comunicados-de-imprensa\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\/","title":{"rendered":"Novo estudo confirma os primeiros resultados de seguran\u00e7a para Rigicon ContiClassic\u00ae: esf\u00edncter urin\u00e1rio artificial, em tratamento masculino incontin\u00eancia urin\u00e1ria de esfor\u00e7o"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Temos o orgulho de anunciar a publica\u00e7\u00e3o do artigo do estudo cl\u00ednico \u201cPrimeiros resultados de seguran\u00e7a para Rigicon ContiClassic: esf\u00edncter urin\u00e1rio artificial\u201d. Este estudo esclarece o perfil de seguran\u00e7a do Rigicon ContiClassic\u00a0no tratamento da incontin\u00eancia urin\u00e1ria de esfor\u00e7o masculina (IUE) e o posiciona como uma op\u00e7\u00e3o compar\u00e1vel e inovadora ao lado das solu\u00e7\u00f5es existentes.<\/p>\n\n\n<p class=\"wp-block-paragraph\">Introduzido no mercado internacional h\u00e1 apenas dois anos, o Rigicon ContiClassic esf\u00edncter urin\u00e1rio artificial rapidamente atraiu a aten\u00e7\u00e3o como uma op\u00e7\u00e3o de tratamento vi\u00e1vel para homens que lutam contra a incontin\u00eancia urin\u00e1ria de esfor\u00e7o.<\/p>\n\n\n<p class=\"wp-block-paragraph\">O estudo centrou-se na demografia dos pacientes, nas complexidades cir\u00fargicas e nas causas subjacentes da incontin\u00eancia, revelando uma efic\u00e1cia louv\u00e1vel numa coorte diversificada de pacientes. Notavelmente, os participantes tinham uma idade m\u00e9dia de 68,3 anos, sendo a incontin\u00eancia urin\u00e1ria relacionada \u00e0 prostatectomia radical respons\u00e1vel por 58,6% dos implantes. De forma encorajadora, o estudo n\u00e3o relatou casos de infec\u00e7\u00f5es ou complica\u00e7\u00f5es significativas. Um destaque do estudo foi o c\u00e1lculo de Kaplan-Meier, demonstrando uma impressionante taxa de sobreviv\u00eancia de 93,2% no marco de 12 meses.<\/p>\n\n\n<p class=\"wp-block-paragraph\">Steven K. Wilson, renomada autoridade em urologia, elogiou as descobertas do estudo, afirmando: &#8220;O Rigicon ContiClassic representa um passo importante no tratamento da incontin\u00eancia urin\u00e1ria de esfor\u00e7o masculina. Seu design inovador e resultados de seguran\u00e7a compar\u00e1veis \u200b\u200bo posicionam como uma escolha valiosa para pacientes que buscam solu\u00e7\u00f5es eficazes&#8221;.<\/p>\n\n\n<p class=\"wp-block-paragraph\"><strong>Sobre incontin\u00eancia urin\u00e1ria<\/strong><\/p>\n\n\n<p class=\"wp-block-paragraph\">A incontin\u00eancia urin\u00e1ria (IU) \u00e9 a perda involunt\u00e1ria de urina. Pacientes que sofrem de incontin\u00eancia urin\u00e1ria n\u00e3o conseguem controlar a libera\u00e7\u00e3o de urina da bexiga. Embora incontin\u00eancia urin\u00e1ria de esfor\u00e7o seja o tipo mais comum, existem diferentes tipos de incontin\u00eancia urin\u00e1ria. A incontin\u00eancia urin\u00e1ria de esfor\u00e7o \u00e9 o vazamento inesperado de urina quando ocorre uma press\u00e3o externa com atividades como levantar peso, tossir, espirrar, rir ou fazer exerc\u00edcios. Essa press\u00e3o externa faz com que a bexiga j\u00e1 enfraquecida vaze urina.<\/p>\n\n\n<p class=\"wp-block-paragraph\">Os esf\u00edncteres urin\u00e1rios enfraquecidos podem ser causados \u200b\u200bpor: Cirurgia na regi\u00e3o p\u00e9lvica ou na pr\u00f3stata, les\u00e3o na uretra, medicamentos, excesso de peso, altera\u00e7\u00f5es com a idade, outras causas. A incontin\u00eancia urin\u00e1ria \u00e9 um problema significativo, afetando dezenas de milh\u00f5es de pacientes. Estima-se que a IU afete 1 em cada 10 homens, com preval\u00eancia crescente associada ao envelhecimento.<\/p>\n\n\n<p class=\"wp-block-paragraph\">Homens com incontin\u00eancia urin\u00e1ria apresentam uma taxa mais elevada de depress\u00e3o e s\u00e3o mais propensos a diminuir a participa\u00e7\u00e3o em atividades (por exemplo, diminuir as horas de trabalho, mudar de emprego ou reformar-se voluntariamente antecipadamente).<\/p>\n\n\n<p class=\"wp-block-paragraph\">A maioria dos pacientes que apresentam incontin\u00eancia urin\u00e1ria semanal n\u00e3o procura atendimento. Muitos que procuraram tratamento acreditam que nenhum foi fornecido e muitos que receberam tratamento continuam a apresentar sintomas preocupantes.<\/p>\n\n\n<p class=\"wp-block-paragraph\"><strong>Sobre esf\u00edncter urin\u00e1rio artificial<\/strong><\/p>\n\n\n<p class=\"wp-block-paragraph\">esf\u00edncter urin\u00e1rio artificial (AUS) \u00e9 um dispositivo m\u00e9dico projetado especificamente para tratar a incontin\u00eancia urin\u00e1ria. esf\u00edncter urin\u00e1rio artificial \u00e9 uma op\u00e7\u00e3o de tratamento cir\u00fargico quando as op\u00e7\u00f5es de tratamento n\u00e3o cir\u00fargico ou comportamental falham.<\/p>\n\n\n<p class=\"wp-block-paragraph\">AUS imitar\u00e1 o papel de um esf\u00edncter urin\u00e1rio saud\u00e1vel (os dois m\u00fasculos que controlam a sa\u00edda da urina da bexiga atrav\u00e9s da uretra). AUS fechar\u00e1 a uretra evitando o vazamento de urina. O paciente apertar\u00e1 uma bomba localizada no escroto para liberar o manguito sobre a uretra e esvaziar. A bra\u00e7adeira retornar\u00e1 ao estado fechado em cerca de 2 minutos para evitar vazamento de urina ap\u00f3s a mic\u00e7\u00e3o.<br\/>O esf\u00edncter urin\u00e1rio artificial \u00e9 amplamente considerado o padr\u00e3o ouro para o tratamento de incontin\u00eancia urin\u00e1ria.<\/p>\n\n\n<p class=\"wp-block-paragraph\"><strong>Sobre Rigicon<\/strong><\/p>\n\n\n<p class=\"wp-block-paragraph\">Rigicon\u00a0\u00e9 especializada na pesquisa, desenvolvimento e fabrica\u00e7\u00e3o de solu\u00e7\u00f5es prot\u00e9ticas urol\u00f3gicas inovadoras, com 30 anos de experi\u00eancia em Urologia. Nosso foco \u00e9 criar um portf\u00f3lio abrangente de produtos para urologistas em todo o mundo. Comprometido em melhorar a qualidade de vida dos pacientes, Rigicon\u00a0se concentra em fornecer tratamentos de ponta que abordam diversas condi\u00e7\u00f5es urol\u00f3gicas, incluindo disfun\u00e7\u00e3o er\u00e9til e incontin\u00eancia urin\u00e1ria.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Temos o orgulho de anunciar a publica\u00e7\u00e3o do artigo do estudo cl\u00ednico \u201cPrimeiros resultados de seguran\u00e7a para Rigicon ContiClassic: esf\u00edncter urin\u00e1rio artificial\u201d. Este estudo esclarece o perfil de seguran\u00e7a do Rigicon ContiClassic\u00a0no tratamento da incontin\u00eancia urin\u00e1ria de esfor\u00e7o masculina (IUE) e o posiciona como uma op\u00e7\u00e3o compar\u00e1vel e inovadora ao lado das solu\u00e7\u00f5es existentes. Introduzido [&hellip;]<\/p>\n","protected":false},"author":0,"featured_media":1295,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[822],"tags":[],"class_list":["post-13973","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-comunicados-de-imprensa"],"acf":{"ce_paper_title":"","ce_year":"","ce_journal":"","ce_doi":"","ce_summary":"","ce_authors":"","ce_objective":"","ce_key_findings":"","ce_conclusion":"","ce_clinical_relevance":"","ce_pdf":null,"ce_logos":null,"ce_featured":false,"ce_keywords":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.9 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>ContiClassic AUS Safety Outcomes Study | Rigicon<\/title>\n<meta name=\"description\" content=\"O estudo Rigicon ContiClassic\u00ae destaca uma taxa de sobreviv\u00eancia de 93,2% em 12 meses, sem infec\u00e7\u00f5es ou complica\u00e7\u00f5es maiores, confirmando sua seguran\u00e7a no tratamento da IUE masculina.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.rigicon.com\/pt-br\/comunicados-de-imprensa\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo estudo confirma os primeiros resultados de seguran\u00e7a para Rigicon ContiClassic\u00ae: esf\u00edncter urin\u00e1rio artificial, em tratamento masculino incontin\u00eancia urin\u00e1ria de esfor\u00e7o\" \/>\n<meta property=\"og:description\" content=\"O estudo Rigicon ContiClassic\u00ae destaca uma taxa de sobreviv\u00eancia de 93,2% em 12 meses, sem infec\u00e7\u00f5es ou complica\u00e7\u00f5es maiores, confirmando sua seguran\u00e7a no tratamento da IUE masculina.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.rigicon.com\/pt-br\/comunicados-de-imprensa\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\/\" \/>\n<meta property=\"og:site_name\" content=\"Rigicon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/rigiconurology\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-23T12:31:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.rigicon.com\/wp-content\/uploads\/2023\/08\/press-releases-detail-page-classic-aus-d-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1440\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@rigiconurology\" \/>\n<meta name=\"twitter:site\" content=\"@rigiconurology\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/comunicados-de-imprensa\\\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/comunicados-de-imprensa\\\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Novo estudo confirma os primeiros resultados de seguran\u00e7a para Rigicon ContiClassic\u00ae: esf\u00edncter urin\u00e1rio artificial, em tratamento masculino incontin\u00eancia urin\u00e1ria de esfor\u00e7o\",\"datePublished\":\"2023-08-23T12:31:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/comunicados-de-imprensa\\\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\\\/\"},\"wordCount\":741,\"publisher\":{\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/comunicados-de-imprensa\\\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.rigicon.com\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/press-releases-detail-page-classic-aus-d-1.png\",\"articleSection\":[\"Comunicados de Imprensa\"],\"inLanguage\":\"pt-BR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/comunicados-de-imprensa\\\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\\\/\",\"url\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/comunicados-de-imprensa\\\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\\\/\",\"name\":\"ContiClassic AUS Safety Outcomes Study | Rigicon\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/comunicados-de-imprensa\\\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/comunicados-de-imprensa\\\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.rigicon.com\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/press-releases-detail-page-classic-aus-d-1.png\",\"datePublished\":\"2023-08-23T12:31:00+00:00\",\"description\":\"O estudo Rigicon ContiClassic\u00ae destaca uma taxa de sobreviv\u00eancia de 93,2% em 12 meses, sem infec\u00e7\u00f5es ou complica\u00e7\u00f5es maiores, confirmando sua seguran\u00e7a no tratamento da IUE masculina.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/comunicados-de-imprensa\\\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/comunicados-de-imprensa\\\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/comunicados-de-imprensa\\\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.rigicon.com\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/press-releases-detail-page-classic-aus-d-1.png\",\"contentUrl\":\"https:\\\/\\\/www.rigicon.com\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/press-releases-detail-page-classic-aus-d-1.png\",\"width\":1440,\"height\":720},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/comunicados-de-imprensa\\\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo estudo confirma os primeiros resultados de seguran\u00e7a para Rigicon ContiClassic\u00ae: esf\u00edncter urin\u00e1rio artificial, em tratamento masculino incontin\u00eancia urin\u00e1ria de esfor\u00e7o\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/#website\",\"url\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/\",\"name\":\"Rigicon\",\"description\":\"Innovative Urological Solutions\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/#organization\"},\"alternateName\":\"Innovative Urological Solutions\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/#organization\",\"name\":\"Rigicon, Inc.\",\"alternateName\":\"Innovative Urological Solutions\",\"url\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.rigicon.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/cropped-Logo-Square-Kopya.jpg\",\"contentUrl\":\"https:\\\/\\\/www.rigicon.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/cropped-Logo-Square-Kopya.jpg\",\"width\":512,\"height\":512,\"caption\":\"Rigicon, Inc.\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/rigiconurology\\\/\",\"https:\\\/\\\/x.com\\\/rigiconurology\",\"https:\\\/\\\/www.instagram.com\\\/rigiconurology\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@Rigicon\\\/podcasts\",\"https:\\\/\\\/www.youtube.com\\\/Rigicon\",\"https:\\\/\\\/www.threads.net\\\/@rigiconurology\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/rigicon\\\/\"],\"description\":\"Rigicon is a global provider of innovative, diverse, and complete portfolio of prosthetic urology options.\",\"email\":\"operations@rigicon.com\",\"telephone\":\"+1 (888) 202-9790\",\"legalName\":\"Rigicon, Inc.\",\"vatID\":\"81-3545645\",\"taxID\":\"81-3545645\",\"duns\":\"045247683\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ContiClassic AUS Safety Outcomes Study | Rigicon","description":"O estudo Rigicon ContiClassic\u00ae destaca uma taxa de sobreviv\u00eancia de 93,2% em 12 meses, sem infec\u00e7\u00f5es ou complica\u00e7\u00f5es maiores, confirmando sua seguran\u00e7a no tratamento da IUE masculina.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.rigicon.com\/pt-br\/comunicados-de-imprensa\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\/","og_locale":"pt_BR","og_type":"article","og_title":"Novo estudo confirma os primeiros resultados de seguran\u00e7a para Rigicon ContiClassic\u00ae: esf\u00edncter urin\u00e1rio artificial, em tratamento masculino incontin\u00eancia urin\u00e1ria de esfor\u00e7o","og_description":"O estudo Rigicon ContiClassic\u00ae destaca uma taxa de sobreviv\u00eancia de 93,2% em 12 meses, sem infec\u00e7\u00f5es ou complica\u00e7\u00f5es maiores, confirmando sua seguran\u00e7a no tratamento da IUE masculina.","og_url":"https:\/\/www.rigicon.com\/pt-br\/comunicados-de-imprensa\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\/","og_site_name":"Rigicon","article_publisher":"https:\/\/www.facebook.com\/rigiconurology\/","article_published_time":"2023-08-23T12:31:00+00:00","og_image":[{"width":1440,"height":720,"url":"https:\/\/www.rigicon.com\/wp-content\/uploads\/2023\/08\/press-releases-detail-page-classic-aus-d-1.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_creator":"@rigiconurology","twitter_site":"@rigiconurology","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.rigicon.com\/pt-br\/comunicados-de-imprensa\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\/#article","isPartOf":{"@id":"https:\/\/www.rigicon.com\/pt-br\/comunicados-de-imprensa\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\/"},"author":{"name":"","@id":""},"headline":"Novo estudo confirma os primeiros resultados de seguran\u00e7a para Rigicon ContiClassic\u00ae: esf\u00edncter urin\u00e1rio artificial, em tratamento masculino incontin\u00eancia urin\u00e1ria de esfor\u00e7o","datePublished":"2023-08-23T12:31:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.rigicon.com\/pt-br\/comunicados-de-imprensa\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\/"},"wordCount":741,"publisher":{"@id":"https:\/\/www.rigicon.com\/pt-br\/#organization"},"image":{"@id":"https:\/\/www.rigicon.com\/pt-br\/comunicados-de-imprensa\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/www.rigicon.com\/wp-content\/uploads\/2023\/08\/press-releases-detail-page-classic-aus-d-1.png","articleSection":["Comunicados de Imprensa"],"inLanguage":"pt-BR"},{"@type":"WebPage","@id":"https:\/\/www.rigicon.com\/pt-br\/comunicados-de-imprensa\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\/","url":"https:\/\/www.rigicon.com\/pt-br\/comunicados-de-imprensa\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\/","name":"ContiClassic AUS Safety Outcomes Study | Rigicon","isPartOf":{"@id":"https:\/\/www.rigicon.com\/pt-br\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.rigicon.com\/pt-br\/comunicados-de-imprensa\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\/#primaryimage"},"image":{"@id":"https:\/\/www.rigicon.com\/pt-br\/comunicados-de-imprensa\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/www.rigicon.com\/wp-content\/uploads\/2023\/08\/press-releases-detail-page-classic-aus-d-1.png","datePublished":"2023-08-23T12:31:00+00:00","description":"O estudo Rigicon ContiClassic\u00ae destaca uma taxa de sobreviv\u00eancia de 93,2% em 12 meses, sem infec\u00e7\u00f5es ou complica\u00e7\u00f5es maiores, confirmando sua seguran\u00e7a no tratamento da IUE masculina.","breadcrumb":{"@id":"https:\/\/www.rigicon.com\/pt-br\/comunicados-de-imprensa\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.rigicon.com\/pt-br\/comunicados-de-imprensa\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/www.rigicon.com\/pt-br\/comunicados-de-imprensa\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\/#primaryimage","url":"https:\/\/www.rigicon.com\/wp-content\/uploads\/2023\/08\/press-releases-detail-page-classic-aus-d-1.png","contentUrl":"https:\/\/www.rigicon.com\/wp-content\/uploads\/2023\/08\/press-releases-detail-page-classic-aus-d-1.png","width":1440,"height":720},{"@type":"BreadcrumbList","@id":"https:\/\/www.rigicon.com\/pt-br\/comunicados-de-imprensa\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/www.rigicon.com\/pt-br\/"},{"@type":"ListItem","position":2,"name":"Novo estudo confirma os primeiros resultados de seguran\u00e7a para Rigicon ContiClassic\u00ae: esf\u00edncter urin\u00e1rio artificial, em tratamento masculino incontin\u00eancia urin\u00e1ria de esfor\u00e7o"}]},{"@type":"WebSite","@id":"https:\/\/www.rigicon.com\/pt-br\/#website","url":"https:\/\/www.rigicon.com\/pt-br\/","name":"Rigicon","description":"Innovative Urological Solutions","publisher":{"@id":"https:\/\/www.rigicon.com\/pt-br\/#organization"},"alternateName":"Innovative Urological Solutions","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.rigicon.com\/pt-br\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/www.rigicon.com\/pt-br\/#organization","name":"Rigicon, Inc.","alternateName":"Innovative Urological Solutions","url":"https:\/\/www.rigicon.com\/pt-br\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/www.rigicon.com\/pt-br\/#\/schema\/logo\/image\/","url":"https:\/\/www.rigicon.com\/wp-content\/uploads\/2024\/07\/cropped-Logo-Square-Kopya.jpg","contentUrl":"https:\/\/www.rigicon.com\/wp-content\/uploads\/2024\/07\/cropped-Logo-Square-Kopya.jpg","width":512,"height":512,"caption":"Rigicon, Inc."},"image":{"@id":"https:\/\/www.rigicon.com\/pt-br\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/rigiconurology\/","https:\/\/x.com\/rigiconurology","https:\/\/www.instagram.com\/rigiconurology\/","https:\/\/www.youtube.com\/@Rigicon\/podcasts","https:\/\/www.youtube.com\/Rigicon","https:\/\/www.threads.net\/@rigiconurology","https:\/\/www.linkedin.com\/company\/rigicon\/"],"description":"Rigicon is a global provider of innovative, diverse, and complete portfolio of prosthetic urology options.","email":"operations@rigicon.com","telephone":"+1 (888) 202-9790","legalName":"Rigicon, Inc.","vatID":"81-3545645","taxID":"81-3545645","duns":"045247683"}]}},"jetpack_featured_media_url":"https:\/\/www.rigicon.com\/wp-content\/uploads\/2023\/08\/press-releases-detail-page-classic-aus-d-1.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.rigicon.com\/pt-br\/wp-json\/wp\/v2\/posts\/13973","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rigicon.com\/pt-br\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.rigicon.com\/pt-br\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.rigicon.com\/pt-br\/wp-json\/wp\/v2\/comments?post=13973"}],"version-history":[{"count":0,"href":"https:\/\/www.rigicon.com\/pt-br\/wp-json\/wp\/v2\/posts\/13973\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.rigicon.com\/pt-br\/wp-json\/wp\/v2\/media\/1295"}],"wp:attachment":[{"href":"https:\/\/www.rigicon.com\/pt-br\/wp-json\/wp\/v2\/media?parent=13973"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.rigicon.com\/pt-br\/wp-json\/wp\/v2\/categories?post=13973"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.rigicon.com\/pt-br\/wp-json\/wp\/v2\/tags?post=13973"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}